On March 20, 2026, Novartis announced an agreement with Synnovation Therapeutics to acquire Pikavation Therapeutics, the subsidiary holding the SNV4818 program. This strategic move aims to enhance treatment outcomes for HR+/HER2- breast cancer patients through precision medicine.
Key deal terms and strategic objectives:
-
Transaction Value: Novartis will provide an upfront payment of $2 billion, with up to $1 billion in additional milestone payments linked to future development and commercial success.
-
Breakthrough Mechanism: SNV4818 is an oral drug designed to selectively target the mutated PI3K$\alpha$ enzyme in cancer cells. Unlike current inhibitors that block both mutant and normal enzymes—often leading to severe side effects—SNV4818 spares healthy cells.
-
Clinical Benefits: By focusing on the mutated form, the drug aims to reduce toxicity, support consistent dosing, and enable easier integration with hormonal therapies and other treatments earlier in the care cycle.
-
Research Progress: The asset is currently undergoing Phase 1/2 clinical evaluation for breast cancer and advanced solid tumors. Preclinical studies have demonstrated robust activity against common PIK3CA mutations and clear selectivity over normal enzymes.
Novartis leadership emphasized that applying this new mutant-selective chemistry precisely targets tumor biology, potentially offering patients a more tolerable and durable therapeutic profile.